These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

540 related items for PubMed ID: 32711549

  • 1. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
    Yang J, Li Y, Zhang Y, Fang X, Chen N, Zhou X, Wang X.
    J Exp Clin Cancer Res; 2020 Jul 25; 39(1):142. PubMed ID: 32711549
    [Abstract] [Full Text] [Related]

  • 2. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
    Go H, Jang JY, Kim PJ, Kim YG, Nam SJ, Paik JH, Kim TM, Heo DS, Kim CW, Jeon YK.
    Oncotarget; 2015 Jun 20; 6(17):15035-49. PubMed ID: 25909227
    [Abstract] [Full Text] [Related]

  • 3. SIRT6 through PI3K/Akt/mTOR signaling pathway to enhance radiosensitivity of non-Small cell lung cancer and inhibit tumor progression.
    Xiong L, Tan B, Lei X, Zhang B, Li W, Liu D, Xia T.
    IUBMB Life; 2021 Sep 20; 73(9):1092-1102. PubMed ID: 34033225
    [Abstract] [Full Text] [Related]

  • 4. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
    Zhao MY, Auerbach A, D'Costa AM, Rapoport AP, Burger AM, Sausville EA, Stass SA, Jiang F, Sands AM, Aguilera N, Zhao XF.
    Clin Cancer Res; 2009 Mar 01; 15(5):1708-20. PubMed ID: 19223503
    [Abstract] [Full Text] [Related]

  • 5. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
    Chen J, Ge X, Zhang W, Ding P, Du Y, Wang Q, Li L, Fang L, Sun Y, Zhang P, Zhou Y, Zhang L, Lv X, Li L, Zhang X, Zhang Q, Xue K, Gu H, Lei Q, Wong J, Hu W.
    Theranostics; 2020 Mar 01; 10(7):3151-3163. PubMed ID: 32194860
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.
    Ma Y, Zhang P, Gao Y, Fan H, Zhang M, Wu J.
    Int J Clin Exp Pathol; 2015 Mar 01; 8(11):14875-84. PubMed ID: 26823817
    [Abstract] [Full Text] [Related]

  • 7. NFYB potentiates STK33 activation to promote cisplatin resistance in diffuse large B-cell lymphoma.
    Feng L, Xu X, Zhao K.
    Leuk Res; 2021 Dec 01; 111():106708. PubMed ID: 34536775
    [Abstract] [Full Text] [Related]

  • 8. The tumor suppressive role of inhibin βA in diffuse large B-cell lymphoma.
    Jiang L, Si T, Yu M, Zeng X, Morse HC, Lu Y, Ouyang G, Zhou JX.
    Leuk Lymphoma; 2018 May 01; 59(5):1202-1212. PubMed ID: 28877610
    [Abstract] [Full Text] [Related]

  • 9. Elevated RNA expression of long non‑coding HOTAIR promotes cell proliferation and predicts a poor prognosis in patients with diffuse large B cell lymphoma.
    Yan Y, Han J, Li Z, Yang H, Sui Y, Wang M.
    Mol Med Rep; 2016 Jun 01; 13(6):5125-31. PubMed ID: 27122348
    [Abstract] [Full Text] [Related]

  • 10. Sirtuin 6 inhibits colon cancer progression by modulating PTEN/AKT signaling.
    Tian J, Yuan L.
    Biomed Pharmacother; 2018 Oct 01; 106():109-116. PubMed ID: 29957460
    [Abstract] [Full Text] [Related]

  • 11. SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway.
    Takagi Y, Shimada K, Shimada S, Sakamoto A, Naoe T, Nakamura S, Hayakawa F, Tomita A, Kiyoi H.
    Cancer Sci; 2016 Sep 01; 107(9):1270-80. PubMed ID: 27348272
    [Abstract] [Full Text] [Related]

  • 12. TCL1 as a hub protein associated with the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma based on proteomics methods.
    Gao HX, Li SJ, Niu J, Ma ZP, Nuerlan A, Xue J, Wang MB, Cui WL, Abulajiang G, Sang W, Zhang W, Li XX.
    Pathol Res Pract; 2020 Feb 01; 216(2):152799. PubMed ID: 31932115
    [Abstract] [Full Text] [Related]

  • 13. ROR1 associates unfavorable prognosis and promotes lymphoma growth in DLBCL by affecting PI3K/Akt/mTOR signaling pathway.
    Mao Y, Xu L, Wang J, Zhang L, Hou N, Xu J, Wang L, Yang S, Chen Y, Xiong L, Zhu J, Fan W, Xu J.
    Biofactors; 2019 May 01; 45(3):416-426. PubMed ID: 30801854
    [Abstract] [Full Text] [Related]

  • 14. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
    Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, Tuskova D, Hudson K, Polanska UM, Grondine M, Mayo M, Dai B, Pfeifer M, Erdmann K, Schwammbach D, Zapukhlyak M, Staiger AM, Ott G, Berdel WE, Davies BR, Cruzalegui F, Trneny M, Lenz P, Barry ST, Lenz G.
    Blood; 2017 Jul 20; 130(3):310-322. PubMed ID: 28202458
    [Abstract] [Full Text] [Related]

  • 15. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma.
    Zhou X, Chen N, Xu H, Zhou X, Wang J, Fang X, Zhang Y, Li Y, Yang J, Wang X.
    J Hematol Oncol; 2020 Jun 16; 13(1):77. PubMed ID: 32546241
    [Abstract] [Full Text] [Related]

  • 16. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
    Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, Pogue E, Ding Z, Lam L, Westin J, Davis RE, Young KH, Medeiros LJ, Ford RJ, Nomie K, Zhang L, Wang M.
    Clin Cancer Res; 2018 Aug 15; 24(16):3967-3980. PubMed ID: 29666304
    [Abstract] [Full Text] [Related]

  • 17. PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
    Zhu F, Guo H, Bates PD, Zhang S, Zhang H, Nomie KJ, Li Y, Lu L, Seibold KR, Wang F, Rumball I, Cameron H, Hoang NM, Yang DT, Xu W, Zhang L, Wang M, Capitini CM, Rui L.
    Leukemia; 2019 Dec 15; 33(12):2898-2911. PubMed ID: 31123343
    [Abstract] [Full Text] [Related]

  • 18. Fc receptor-like 1 (FCRL1) is a novel biomarker for prognosis and a possible therapeutic target in diffuse large B-cell lymphoma.
    Yousefi Z, Sharifzadeh S, Zare F, Eskandari N.
    Mol Biol Rep; 2023 Feb 15; 50(2):1133-1145. PubMed ID: 36409389
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
    Szydłowski M, Garbicz F, Jabłońska E, Górniak P, Komar D, Pyrzyńska B, Bojarczuk K, Prochorec-Sobieszek M, Szumera-Ciećkiewicz A, Rymkiewicz G, Cybulska M, Statkiewicz M, Gajewska M, Mikula M, Gołas A, Domagała J, Winiarska M, Graczyk-Jarzynka A, Białopiotrowicz E, Polak A, Barankiewicz J, Puła B, Pawlak M, Nowis D, Golab J, Tomirotti AM, Brzózka K, Pacheco-Blanco M, Kupcova K, Green MR, Havranek O, Chapuy B, Juszczyński P.
    Cancer Res; 2021 Dec 01; 81(23):6029-6043. PubMed ID: 34625423
    [Abstract] [Full Text] [Related]

  • 20. Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.
    Wang J, Zhang Y, Liu X, Ma J, Liu P, Hu C, Zhang G.
    Oncol Rep; 2014 Dec 01; 32(6):2557-63. PubMed ID: 25323007
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.